Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Double-blind Assessment of the Presence of Fluorescence Signature to Predict Graft Failure Using MolecuLight i:X Imaging Device

NCT04185636 is registered in ClinicalTrials.gov with MolecuLight Inc. as lead sponsor.

NCT NCT04185636
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04185636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Double-blind Assessment of the Presence of Fluorescence Signature to Predict Graft Failure Using MolecuLight i:X Imaging Device
Lead sponsor
MolecuLight Inc.
Phase
Observational
Overall status
Unknown status
Start date
January 15, 2021
Completion date
June 15, 2022
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

skin graft (allograft)(autograft) failure